VCaP

VCaP (Prostate Cancer CDX Model)

The VCaP prostate cancer line was derived from a vertebral bone metastasis of prostate carcinoma. It is androgen receptor–positive and expresses prostate-specific antigen (PSA). VCaP carries the TMPRSS2-ERG gene fusion, a frequent alteration in prostate cancer. Its biology provides strong translational relevance for AR-driven research.

Key Features:

• Derived from vertebral metastasis of prostate cancer.
• Androgen receptor–positive, PSA-expressing.
• Contains TMPRSS2-ERG gene fusion.
• Tumorigenic in xenografts.

Applications:
VCaP is applied in studies of androgen receptor signaling and therapeutic development. Researchers use it to evaluate anti-androgen and combination therapies. It supports biomarker research, particularly involving ERG fusions. Its metastasis-derived biology makes it valuable in advanced prostate cancer pipelines.